[1] Gu M J, Huang Q C, Bao C Z, et al. Attributable causes of colorectal cancer in China[J]. BMC Cancer, 2018, 18(1):38. [2] Arriola E, Navarro M, Parés D, et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer[J]. Diseases of the Colon and Rectum, 2006, 49(4):478-484. [3] Guney I B, Teke Z, Kucuker K A, et al. A prospective comparative study of contrast-enhanced CT, contrast-enhanced MRI and 18F-FDG PET/CT in the preoperative staging of colorectal cancer patients[J]. Annali Italiani di Chirurgia, 2020, 91:658-667. [4] Lee D H, Lee J M. Whole-body PET/MRI for colorectal cancer staging:Is it the way forward?[J]. Journal of Magnetic Resonance Imaging, 2017, 45(1):21-35. [5] Tsili A C, Alexiou G, Naka C, et al. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT:A meta-analysis[J]. Acta Radiologica:Stockholm, Sweden:1987, 2021, 62(3):302-312. [6] Caresia Aroztegui A P, García Vicente A M, Alvarez Ruiz S, et al. 18F-FDG PET/CT in breast cancer:Evidence-based recommendations in initial staging[J]. Tumour Biology, 2017, 39(10):1010428317728285. [7] Castello A, Rossi S, Lopci E. 18F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer:State of the art[J]. Current Radiopharmaceuticals, 2020, 13(3):228-237. [8] Paydary K, Seraj S M, Zadeh M Z, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer[J]. Molecular Imaging and Biology, 2019, 21(1):1-10. [9] 黄慧. 18F-FDG PET/CT显像在结直肠癌术后复发中的应用价值[D]. 天津:天津医科大学, 2015. [10] 田蓉蓉, 薄云峰, 张毅勋, 等. 18F-FDG PET/CT术前诊断结直肠癌区域淋巴结转移的价值[J]. 中国医学影像学杂志, 2017, 25(11):801-806. [11] 王大龙, 于丽娟, 田墨涵, 等. 18F-FDG PET/CT显像在结直肠癌术前分期中的价值[J]. 临床放射学杂志, 2012, 31(1):70-74. [12] Gartel A L. FOXM1 in cancer:Interactions and vulnerabilities[J]. Cancer Research, 2017, 77(12):3135-3139. [13] Liao G B, Li X Z, Zeng S, et al. Regulation of the master regulator FOXM1 in cancer[J]. Cell Communication and Signaling, 2018, 16(1):57. [14] Yao S, Fan L Y N, Lam E W F. The FOXO3-FOXM1 axis:A key cancer drug target and a modulator of cancer drug resistance[J]. Seminars in Cancer Biology, 2018, 50:77-89. [15] Li Q, Zhang N, Jia Z L, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression[J]. Cancer Research, 2009, 69(8):3501-3509. [16] Varghese V, Magnani L, Harada-Shoji N, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression[J]. Scientific Reports, 2019, 9(1):1505. [17] Yang Y H, Jiang H Q, Li W X, et al. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer[J]. Aging, 2020, 12(23):24424-24440. [18] Biller L H, Schrag D. Diagnosis and treatment of metastatic colorectal cancer:A review[J]. JAMA, 2021, 325(7):669-685. [19] Dekker E, Tanis P J, Vleugels J L A, et al. Colorectal cancer[J]. Lancet:London, England, 2019, 394(10207):1467-1480. [20] Sokolovi E, Ceri T, Ceri Š, et al. The Prognostic value of SUVmax of 18F-FDG PET/CT in patients with metastatic colorectal cancer[J]. Acta Medica Academica, 2020, 49(1):1-8. [21] Kaida H, Toh U, Hayakawa M, et al. The relationship between 18F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancer[J]. Nuclear Medicine Communications, 2013, 34(6):562-570. [22] Kim D H, Song B I, Hong C M, et al. Metabolic parameters using 18F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41(11):2051-2057. [23] Im H J, Oo S, Jung W, et al. Prognostic value of metabolic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer[J]. Medicine, 2016, 95(19):e3686. [24] Ogawa S, Itabashi M, Kondo C, et al. Prognostic value of total lesion glycolysis measured by 18F-FDG-PET/CT in patients with colorectal cancer[J]. Anticancer Research, 2015, 35(6):3495-3500. [25] 丁重阳, 郭喆, 孙晋, 等. 18氟-氟代脱氧葡萄糖PET/CT检查判断胰腺癌预后的临床价值[J]. 中华消化外科杂志, 2017, 16(10):1072-1080. [26] Xu J Y, Li Y, Hu S L, et al. The significant value of predicting prognosis in patients with colorectal cancer using (18)F-FDG PET metabolic parameters of primary tumors and hematological parameters[J]. Annals of Nuclear Medicine, 2019, 33(1):32-38. [27] Chen S W, Chen W T L, Wu Y C, et al. Which FDG/PET parameters of the primary tumors in colon or sigmoid cancer provide the best correlation with the pathological findings?[J]. European Journal of Radiology, 2013, 82(9):e405-e410. [28] 贾朝阳. 18F-FDG PET/CT显像在结直肠癌中的应用价值[D]. 天津:天津医科大学, 2019. [29] Lin J Z, Wang W W, Hu T T, et al. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy[J]. Cancer Letters, 2020, 469:481-489. [30] Ros S, Wright A J, D’Santos P, et al. Metabolic imaging detects resistance to PI3Kα inhibition mediated by persistent FOXM1 expression in ER(+) breast cancer[J]. Cancer Cell, 2020, 38(4):516-533.e9. [31] Sun H L, Men J R, Liu H Y, et al. FOXM1 facilitates breast cancer cell stemness and migration in YAP1-dependent manner[J]. Archives of Biochemistry and Biophysics, 2020, 685:108349. [32] Zhang S C, Zhao B S, Zhou A D, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program[J]. Cancer Cell, 2017, 31(4):591-606.e6. [33] 袁浩, 李永平, 蒋晓飞, 等. 抑制FoxM1基因表达对甲状腺乳头状癌TPC-1细胞糖酵解途径的影响[J]. 肿瘤防治研究, 2019, 46(4):289-293. |